Methyl 2-(chlorosulfonylmethyl)benzoate | CAS:103342-27-4

We serve Methyl 2-(chlorosulfonylmethyl)benzoate CAS:103342-27-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Methyl 2-(chlorosulfonylmethyl)benzoate

CAS No: 103342-27-4
Product Name: Methyl 2-(chlorosulfonylmethyl)benzoate
Other Name:
Methyl 2-(chlorosulfonylmethyl)benzoate
o-Methoxycarbonyl benzyl sulfonyl chloride
 
Molecular Formula: C9H9ClO4S
Molecular Weight: 248.68300
Exact Mass: 247.99100
PSA: 68.82000
LogP: 2.62260
 
Specification
Appearance: White solid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Bensulfuron-Methyl CAS: 83055-99-6.
Be used as pesticide intermediate. O-methoxycarbonyl benzylsulfonyl chloride is an intermediate of the herbicide bensulfuron-methyl.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like Methyl 2-(chlorosulfonylmethyl)benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,o-Methoxycarbonyl benzyl sulfonyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl 2-(chlorosulfonylmethyl)benzoate Use and application,Methyl 2-(chlorosulfonylmethyl)benzoate technical grade,usp/ep/jp grade.


Related News: Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).10-(2-Naphthyl)Anthracene-9-Boronic Acid manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Pentafluorobenzoic acid supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).4-(methylamino)-3-nitrobenzoyl chloride vendor China is now dealing with another disease outbreak — this one mostly affecting animals but also potentially deadly among people.The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.